持续的 CD19+ 细胞耗竭后稳定的 HLA 抗体提示存在长寿浆细胞来源。
Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source.
机构信息
Department of Hematology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China; and.
Department of Pathology and Laboratory Medicine.
出版信息
Blood Adv. 2020 Sep 22;4(18):4292-4295. doi: 10.1182/bloodadvances.2020002435.
Abstract
HLA-specific alloantibodies can be maintained despite profound CD19 cell aplasia, likely due to production by CD19 plasma cells.
摘要
尽管存在严重的 CD19 细胞缺失，但 HLA 特异性同种抗体仍可维持，可能是由于 CD19 浆细胞产生所致。
相似文献
1
Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source.持续的 CD19+ 细胞耗竭后稳定的 HLA 抗体提示存在长寿浆细胞来源。
Blood Adv. 2020 Sep 22;4(18):4292-4295. doi: 10.1182/bloodadvances.2020002435.
2
Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.自身反应性CD19+CD20-浆细胞促进实验性自身免疫性脑脊髓炎的疾病严重程度。
J Immunol. 2016 Feb 15;196(4):1541-9. doi: 10.4049/jimmunol.1501376. Epub 2016 Jan 13.
3
Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.长寿浆细胞存在于人类骨髓中的CD19(-)CD38(hi)CD138(+)亚群内。
Immunity. 2015 Jul 21;43(1):132-45. doi: 10.1016/j.immuni.2015.06.016. Epub 2015 Jul 14.
4
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.对CD19导向的嵌合抗原受体T细胞疗法有反应的个体中长寿浆细胞和体液免疫的持久性。
Blood. 2016 Jul 21;128(3):360-70. doi: 10.1182/blood-2016-01-694356. Epub 2016 May 10.
5
A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow.人类骨髓中富含一种独特的 IgG 表达浆细胞群体，该群体缺乏 CD19。
Blood. 2015 Mar 12;125(11):1739-48. doi: 10.1182/blood-2014-02-555169. Epub 2015 Jan 8.
6
Characterization of antigen-presenting cells in human apical periodontitis lesions by flow cytometry and immunocytochemistry.通过流式细胞术和免疫细胞化学对人类根尖周炎病变中抗原呈递细胞的表征。
Int Endod J. 2006 Aug;39(8):626-36. doi: 10.1111/j.1365-2591.2006.01125.x.
7
Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients.肾移植患者接受B淋巴细胞清除治疗后外周同种异体特异性CD19+B细胞亚群的重建。
Transplantation. 2009 May 15;87(9):1394-401. doi: 10.1097/TP.0b013e3181a27683.
8
CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.CD19-CD45 低/-CD38 高/CD138+ 浆细胞富集人致瘤性骨髓瘤细胞。
Leukemia. 2012 Dec;26(12):2530-7. doi: 10.1038/leu.2012.140. Epub 2012 May 30.
9
Thucydides and longer-lived plasma cells.修昔底德与寿命更长的浆细胞。
Blood. 2015 Mar 12;125(11):1684-5. doi: 10.1182/blood-2015-01-622514.
10
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response.在二次免疫应答中迁移性抗原特异性浆母细胞的产生及驻留浆细胞的动员。
Blood. 2005 Feb 15;105(4):1614-21. doi: 10.1182/blood-2004-07-2507. Epub 2004 Oct 26.
引用本文的文献
1
Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies.针对 B 细胞和长寿浆细胞的免疫疗法可有效消除预先存在的供体特异性同种抗体。
Cell Rep Med. 2023 Dec 19;4(12):101336. doi: 10.1016/j.xcrm.2023.101336.
2
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.接受 CD19 与 BCMA 靶向 CAR T 细胞治疗的患者中的抗 HLA 抗体。
Am J Transplant. 2023 Mar;23(3):416-422. doi: 10.1016/j.ajt.2022.11.001. Epub 2023 Jan 12.
3
Therapeutic Opportunities for Immunoreceptor-Engineered T Cell Therapy for Modulation of Alloimmunity.免疫受体工程化 T 细胞治疗在调节同种异体免疫中的治疗机会。
J Immunol. 2022 Nov 15;209(10):1811-1816. doi: 10.4049/jimmunol.2200542.
4
Antibody-mediated rejection after kidney transplantation in children; therapy challenges and future potential treatments.儿童肾移植后抗体介导的排斥反应；治疗挑战和未来潜在治疗方法。
Clin Transplant. 2022 Apr;36(4):e14608. doi: 10.1111/ctr.14608. Epub 2022 Feb 16.
本文引用的文献
1
Novel therapeutic opportunities afforded by plasma cell biology in transplantation.在移植中浆细胞生物学带来的新治疗机会。
Am J Transplant. 2020 Aug;20(8):1984-1991. doi: 10.1111/ajt.15813. Epub 2020 Feb 29.
2
Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice.人类白细胞抗原致敏及其对输血实践的影响。
Transfus Med Hemother. 2019 Oct;46(5):356-369. doi: 10.1159/000502158. Epub 2019 Aug 29.
3
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.嵌合抗原受体 T 细胞免疫疗法后抗 CD19 定向的抗病毒抗体的持久保存。
Blood Adv. 2019 Nov 26;3(22):3590-3601. doi: 10.1182/bloodadvances.2019000717.
4
The Pharmacology of T Cell Therapies.T细胞疗法的药理学
Mol Ther Methods Clin Dev. 2018 Jan 31;8:210-221. doi: 10.1016/j.omtm.2018.01.010. eCollection 2018 Mar 16.
5
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
6
Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.实体器官移植中的抗体介导性排斥反应：表现、机制及治疗方法
J Clin Invest. 2017 Jun 30;127(7):2492-2504. doi: 10.1172/JCI90597. Epub 2017 Jun 12.
7
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.一线利妥昔单抗联合短期泼尼松与单独泼尼松治疗天疱疮（Ritux 3）：一项前瞻性、多中心、平行组、开放标签随机试验。
Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22.
8
Antibody-Mediated Rejection Due to Preexisting versus Donor-Specific Antibodies in Kidney Allograft Recipients.肾移植受者中，由预先存在的抗体与供体特异性抗体导致的抗体介导的排斥反应。
J Am Soc Nephrol. 2017 Jun;28(6):1912-1923. doi: 10.1681/ASN.2016070797. Epub 2017 Mar 2.
9
Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植中的供者特异性抗HLA抗体
Front Immunol. 2016 Aug 12;7:307. doi: 10.3389/fimmu.2016.00307. eCollection 2016.
10
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.对CD19导向的嵌合抗原受体T细胞疗法有反应的个体中长寿浆细胞和体液免疫的持久性。
Blood. 2016 Jul 21;128(3):360-70. doi: 10.1182/blood-2016-01-694356. Epub 2016 May 10.
Zotero 插件